



MedDRA
Medical Dictionary
for Regulatory Activities

Standardised MedDRA Queries (SMQs)





ICH
harmonisation for better health 1



MedDRA

MedDRA was developed under the auspices of the International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use (ICH). The activities of the MedDRA Maintenance and Support Services Organization (MSSO) are overseen by an ICH MedDRA Management Committee, which is composed of the ICH parties, the Medicines and Healthcare products Regulatory Agency (MHRA) of the UK, Health Canada, and the WHO (as Observer).



ICH
harmonisation for better health 2

000687



MedDRA

Disclaimer & Copyright Notice

- This presentation is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the presentation is acknowledged at all times. In case of any adaptation, modification or translation of the presentation, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original presentation. Any impression that the adaptation, modification or translation of the original presentation is endorsed or sponsored by the ICH must be avoided.
- The presentation is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original presentation be liable for any claim, damages or other liability arising from the use of the presentation.
- The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

000687

3



MedDRA

Course Overview

- Review content of the MedDRA Data Retrieval and Presentation: Points to Consider document
- Discuss the features of Standardised MedDRA Queries (SMQs) including:
 - Background and data characteristics
 - Impact of MedDRA versioning on SMQs
 - Benefits/limitations of SMQs

000687

4



MedDRA

Course Overview (cont)

- Demonstration of SMQ Analysis Tool embedded in MedDRA browsers
- SMQ applications
- Two clinical scenarios for the use of SMQs
- Discuss the creation of customized searches
- Conclude with question and answer session

000687

5



MedDRA

MedDRA Data Retrieval and Presentation: Points to Consider

000687

6



MedDRA

MedDRA Data Retrieval and Presentation: Points to Consider (DRP:PTC)

MedDRA® DATA RETRIEVAL AND PRESENTATION: POINTS TO CONSIDER ICH-Endorsed Guide for MedDRA Users on Data Output

Release 3.22

March 2022

Disclaimer and Copyright Notice

This document is protected by copyright and may, with the exception of the MedDRA and ICH logos, be used, reproduced, incorporated into other works, adapted, modified, translated or distributed under a public license provided that ICH's copyright in the document is acknowledged at all times. In case of any adaptation, modification or translation of the document, reasonable steps must be taken to clearly label, demarcate or otherwise identify that changes were made to or based on the original document. Any impression that the adaptation, modification or translation of the original document is endorsed or sponsored by the ICH must be avoided.

The document is provided "as is" without warranty of any kind. In no event shall the ICH or the authors of the original document be liable for any claim, damages or other liability arising from the use of the document.

The above-mentioned permissions do not apply to content supplied by third parties. Therefore, for documents where the copyright vests in a third party, permission for reproduction must be obtained from this copyright holder.

MedDRA® trademark is registered by ICH

000687

- Provides data retrieval and presentation options for industry or regulatory purposes
- Most effective when used in conjunction with MedDRA Term Selection: PTC document
- Recommended to be used as basis for individual organization's own data retrieval conventions

7



MedDRA

MedDRA Data Retrieval and Presentation: PTC (cont)

- Developed by a working group of the ICH Management Committee
- Updated annually - March
- Complete versions available in
 - English, Japanese, Chinese, Korean, Spanish, and Russian
- Condensed versions available for other MedDRA languages
- Available on MedDRA and JMO websites



000687

8



Data Retrieval and Presentation : PTC

Points Addressed

- General Principles
 - Quality of Source Data
 - Documentation of Data Retrieval and Presentation Practices
 - Do Not Alter MedDRA
 - Organisation-Specific Data Characteristics
 - Characteristics of MedDRA that Impact Data Retrieval and Analysis
 - MedDRA Versioning
- General Queries and Retrieval
- Standardised MedDRA Queries
- Customised Searches

000687

9



MedDRA Versioning

MedDRA is updated twice a year

- ✓ 1 March X.0 release (all levels)
- ✓ 1 September X.1 release (LLT and PT levels only)

Version used in data retrieval and presentation should be documented

Resources

- “What’s New” document
- Version report
- MedDRA Version Analysis Tool (MVAT)

Terms used for queries should be in the same version as data being queried

000687

10



MedDRA Version Analysis Tool (MVAT)

- Web-based (<https://tools.meddra.org/mvat>)
- Free to all users
- Features
 - Version Report Generator (produces exportable report comparing any two versions)
 - Data Impact Report (identifies changes to a specific set of MedDRA terms or codes uploaded to MVAT)
 - Search Term Change (identifies changes to a single MedDRA term or code)

000687

11



MedDRA Version Analysis Tool (MVAT) (cont)

- User interface and report output available in all MedDRA languages
- Ability to run reports on supplemental changes
- Option to run reports on secondary SOC changes
- Watch the two-part webinar on the use of MVAT under "Tools" tab on the "Training Materials" page of MedDRA website

<https://www.meddra.org/training-materials>

000687

12



Standardised MedDRA Queries (SMQs)


000687

13




What is a Query?

Clinical Trial Database
Safety Database



Query



"Hit"

000687

14



Standardised MedDRA Queries (SMQs)

Groupings of terms from one or more MedDRA SOCs related to medical condition or area of interest

- Terms relate to
 - ✓ Signs/symptoms,
 - ✓ Diagnoses,
 - ✓ Syndromes,
 - ✓ Physical findings,
 - ✓ Laboratory and other test data, etc.
- Intended to aid in case identification

000687

15



SMQs in Production - Examples

As of Version 25.0, a total of 110 level 1 SMQs in production

- Agranulocytosis
- Anaphylactic reaction
- Central nervous system vascular disorders
- Convulsions
- COVID-19
- Depression and suicide/self-injury
- Hepatic disorders
- Hypersensitivity
- Ischaemic heart disease
- Lack of efficacy/effect
- Medication errors
- Osteonecrosis
- Peripheral neuropathy
- Pregnancy and neonatal topics
- Pseudomembranous colitis
- Rhabdomyolysis/myopathy
- Severe cutaneous adverse reactions
- Shock
- Systemic lupus erythematosus

000687

16



MedDRA

SMQ Data Characteristics

- MedDRA term inclusion
- Broad/narrow
- Algorithms
- Hierarchy
- SMQ status/term status within an SMQ
- Term versioning in an SMQ

000687

17



MedDRA

MedDRA Term Inclusion

- SMQs are constructed at MedDRA PT level
- LLTs that are subordinate to an included PT are also included

System Organ Class (SOC)	27
High Level Group Term (HLGT)	337
High Level Term (HLT)	1737
{ Preferred Term (PT) Lowest Level Term (LLT)	25412
	85091

000687

MedDRA Version 25.0


18



MedDRA

Narrow and Broad Searches

- “**Narrow**” scope – specificity (cases highly likely to be condition of interest)
- “**Broad**” scope – sensitivity (all possible cases)
- “Broad search” = All broad + all narrow terms



MedDRA

Narrow vs. Broad Example

Lactic acidosis (SMQ)

Narrow search terms

- Blood lactic acid increased
- Hyperlactacidaemia
- Lactic acidosis

Broad Search Terms

- Acid base balance abnormal
- Acidosis
- Anion gap abnormal
- Anion gap increased
- Blood alkalisation therapy
- Blood bicarbonate abnormal
- Blood bicarbonate decreased
- Blood gases abnormal
- Blood lactic acid abnormal
- Blood pH abnormal
- Blood pH decreased
- Carbon dioxide combining power abnormal
- Carbon dioxide combining power decreased
- Coma acidotic
- Kussmaul respiration
- Metabolic acidosis
- PCO2 abnormal
- PCO2 decreased
- Urine lactic acid increased

Definition

Lactic acidosis is a form of high anion gap metabolic acidosis - Intrinsic cardiac contractility may be depressed, but inotropic function can be normal because of catecholamine release- Peripheral arterial vasodilatation and central vasoconstriction can be present - Central nervous system function is depressed, with headache, lethargy, stupor, and, in some cases, even coma - Glucose intolerance may occur - Characterized by an increase in plasma L-lactate - Acidosis is seldom significant unless blood lactate exceeds 5 mmol/l - Clinical presentation in type B lactic acidosis: o Symptoms: hyperventilation or dyspnea, stupor or coma, vomiting, drowsiness, and abdominal pain o Onset of symptoms and signs is usually rapid accompanied by deterioration in the level of consciousness.

Source

1. Braunwald E, Fauci A, Kasper D. Harrison's Principles of Internal Medicine. 15th Edition, 2001 pp 285-92. Weatherall D, Ledingham J and Warrell D. Oxford Textbook of Medicine. Third edition, 1996; volume 2 pp 1541-44

Note

Testing in two regulatory databases confirmed that the term list is adequate, in one regulatory database, the term "acidosis" identified cases, but this may be a phenomenon of the database characteristics (coding of verbatims to terms of an older terminology or other coding conventions).

000687


20



MedDRA

Algorithmic SMQs

- Some SMQs are designed to utilize algorithms



- Better case identification among broad search terms may result if cases are selected by a defined combination of selected terms

000687

21



MedDRA

Algorithmic SMQ Example (cont)

<i>Anaphylactic reaction (SMQ)</i>	
Category A = Narrow search terms	Category B = Upper airway/Respiratory
<ul style="list-style-type: none"> • Anaphylactic reaction • Anaphylactic shock • Anaphylactic transfusion reaction • Anaphylactoid reaction • Anaphylactoid shock • Circulatory collapse • Dialysis membrane reaction • Kounis syndrome • Procedural shock • Shock • Shock symptom • Type I hypersensitivity 	<ul style="list-style-type: none"> • Acute respiratory failure • Asthma • Bronchial oedema
	Category C = Angioedema/Urticaria, etc.
	<ul style="list-style-type: none"> • Allergic oedema • Angioedema • Erythema
	Category D = Cardiovascular/Hypotension
	<ul style="list-style-type: none"> • Blood pressure decreased • Blood pressure diastolic decreased • Blood pressure systolic decreased



A case =

- Term Category **A** (Narrow terms)
- or** – Term from Category **B** **and** term from Category **C**
- Term from **either** [Category **B** or Category **C**] **plus** Term from Category **D**

Not all Category B, C, and D terms are shown


000687

22





Hierarchical SMQ Example



SMQ Status/Term Status

- Each SMQ has a status (Active/Inactive)
- Similar in concept to MedDRA currency
- Terms assigned to an SMQ also have a status flag
 - Once a term is added to an SMQ, it will always be included in the SMQ but the status may be inactive

000687

26



MedDRA

SMQ Versioning

- It is recommended that organizations use the SMQs with data coded with the same version of MedDRA
 - Match the MedDRA version of the SMQ with the MedDRA version of the coded data
 - Mismatches of SMQ and MedDRA coded data could produce unexpected results

000687

27




MedDRA

SMQ Versioning (cont)

- Example of PT added to SMQs in MedDRA Version 23.0:
 - PT *Hormone receptor positive breast cancer* in SMQ *Breast malignant tumours*
- Using version 22.1 SMQs which do not contain these PTs would fail to identify cases coded to these terms in a database using MedDRA Version 23.0


000687

28




MedDRA

SMQ Benefits and Limitations



Benefits


- Application across multiple therapeutic areas
- Validated reusable search logic
- Standardized communication of safety information
- Consistent data retrieval
- Maintenance by MSSO/JMO



Limitations

- Do not cover all medical topics or safety issues
- Will evolve and undergo further refinement even though they have been tested during development

000687 29



MedDRA

Browser Demonstration SMQ View

000687 30



Using the SMQ Analysis Tool in the MedDRA Browsers

000687

31



MSSO's MedDRA Browsers



MedDRA Desktop Browser (MDB)
Download MDB and release files from MedDRA website

MedDRA Web-Based Browser (WBB)
<https://tools.meddra.org/wbb/>

000688



Mobile MedDRA Browser

<https://mmb.meddra.org>

32



MSSO's MedDRA Browsers (cont)

- Features
 - Each require MedDRA ID and password
 - View/search MedDRA and SMQs
 - Support for all MedDRA languages
 - Language specific interface
 - Ability to export search results and Research Bin to local file system (MDB and WBB only)



000687

33



MDB and WBB Special Features

- Preview upcoming (supplemental) changes in next release*

**Supplemental view not available on MDB*

- View primary **and** secondary link information
- Upload terms to run against SMQs
- Advanced search options (e.g., NOT, OR)



000687

34



MedDRA

How to “Run” SMQs

- IT perspective of SMQs = stored queries
- Most organizations code and store data as LLTs
- SMQ ASCII files include PTs and LLTs
- Load SMQs into a query tool; run query against coded MedDRA terms in database for “Hits”
- Use SMQ options, if applicable
 - ✓ Narrow/broad search
 - ✓ Algorithms
 - ✓ Hierarchy

000687

35



MedDRA

A Practical Question

- In my dataset, which cases are “hits” for SMQs (potential cases of interest)?

Row ID	Term	Code	Case ID
1	Amylase abnormal	10072327	1
2	Abdominal distension	10000060	1
3	Acute kidney injury	10069339	2
4	Blood creatinine increased	10005483	2
5	Status asthmaticus	10041961	3
6	Gout	10018627	4
7	Joint effusion	10023215	4
8	Major depression	10057840	5
9	Suicidal ideation	10042458	5
10	Cataract operation	10063797	6
11	Abdominal pain	10000081	7
12	Diarrhoea	10012735	7
13	Palpitations	10033557	8
14	Atrial flutter	10003662	8
15	Pancreatitis acute	10033647	9
16	Dementia Alzheimer's type	10012271	10
17	Hypertension	10020772	10
18	Anaphylactic shock	10002199	11
19	Bronchospasm	10006482	12
20	Swelling face	10042682	12
21	Rash	10037844	12
22	Hypotension	10021097	12
23	SLE arthritis	10040968	13
24	Haemolysis	10018910	14
25	Autoimmune nephritis	10077087	14
26	Double stranded DNA antibody positive	10069907	14
27	Photodermatosis	10051246	15
28	Pleural effusion	10035598	15
29	Epilepsy	10015037	15
30	Disease progression	10061818	16
31	Exercise tolerance decreased	10051301	16
32	COVID-19 pneumonia	10084380	17
33	Acute respiratory distress syndrome	10001052	17

Input


000687

36



Standardised MedDRA Query (SMQ) Analysis Tool

- SMQ Analysis feature
- Apply SMQs to user's MedDRA-coded data
 - Narrow/broad
 - Hierarchical
 - Algorithmic (separate search option to apply algorithm)



000687

37



SMQ Analysis Tool (cont)

- Run broad search of all SMQs

Row ID	Term	Code	Case ID
1	Amylase abnormal	10072327	1
2	Abdominal distension	10000060	1
3	Acute kidney injury	10069339	2
4	Blood creatinine increased	10005483	2
5	Status asthmaticus	10041961	3
6	Gout	10018627	4
7	Joint effusion	10023215	4
8	Major depression	10057840	5
9	Suicidal ideation	10042458	5
10	Cataract operation	10063797	6
11	Abdominal pain	10000081	7
12	Diarrhoea	10012735	7
13	Palpitations	10033557	8
14	Atrial flutter	10003662	8
15	Pancreatitis acute	10033647	9
16	Dementia Alzheimer's type	10012271	10
17	Hypertension	10020772	10
18	Anaphylactic shock	10002199	11
19	Bronchospasm	10006482	12
20	Swelling face	10042682	12
21	Rash	10037844	12
22	Hypotension	10021097	12
23	SLE arthritis	10040968	13
24	Haemolysis	10018910	14
25	Autoimmune nephritis	10077087	14
26	Double stranded DNA antibody positive	10069907	14
27	Photodermatosis	10051246	15
28	Pleural effusion	10035598	15
29	Epilepsy	10015037	15
30	Disease progression	10061818	16
31	Exercise tolerance decreased	10051301	16
32	COVID-19 pneumonia	10084380	17
33	Acute respiratory distress syndrome	10001052	17

Input

000687

38



MedDRA

SMQ Analysis Tool (cont)

- Results of broad search on all SMQs
 - Includes narrow search
 - Includes hierarchical SMQs
 - Algorithmic SMQ analysis not shown

Row ID	LLT/PT Term	LLT/PT Code	PT	SMQ Matched	Scope	Category	Weight	Status	Case ID	SMQ Level 1	
6	1	Amylase abnormal	10072327	Amylase abnormal	Acute pancreatitis (SMQ)	Broad	B	0	Active	1	Acute pancreatitis (SMQ)
7	2	Abdominal distension	10000060	Abdominal distension	Acute pancreatitis (SMQ)	Broad	C	0	Active	1	Acute pancreatitis (SMQ)
8	18	Abdominal distension	10000060	Abdominal distension	Gastrointestinal nonspecific symptoms and therapeutic procedures (SMQ)	Narrow	A	0	Active	1	Gastrointestinal nonspecific inflammatory and dysfunctional
9	5	Acute kidney injury	10069339	Acute kidney injury	Rhabdomyolysis/myopathy (SMQ)	Broad	A	0	Active	5	Rhabdomyolysis/myopathy (SMQ)
10	5	Acute kidney injury	10069339	Acute kidney injury	Shock-associated circulatory or cardiac conditions (excl torsade de pointes) (SMQ)	Broad	A	0	Active	5	Shock (SMQ)
11	3	Acute kidney injury	10069339	Acute kidney injury	Torsade de pointes, shock-associated conditions (SMQ)	Broad	A	0	Active	2	Shock (SMQ)
12	5	Acute kidney injury	10069339	Acute kidney injury	Hypovolaemic shock conditions (SMQ)	Broad	A	0	Active	2	Shock (SMQ)
13	3	Acute kidney injury	10069339	Acute kidney injury	Toxic-septic shock conditions (SMQ)	Broad	A	0	Active	2	Shock (SMQ)

000687

39



MedDRA

SMQ Analysis Tool (cont)

- Results of algorithmic SMQ analysis

Row ID	LLT/PT Term	LLT/PT Code	PT	SMQ Matched	Scope	Category	Weight	Status	Case ID	SMQ Level 1	
6	1	Amylase abnormal	10072327	Amylase abnormal	Acute pancreatitis (SMQ)	Broad	B	0	Active	1	Acute pancreatitis (SMQ)
7	2	Abdominal distension	10000060	Abdominal distension	Acute pancreatitis (SMQ)	Broad	C	0	Active	1	Acute pancreatitis (SMQ)
8	18	Anaphylactic shock	10002199	Anaphylactic shock	Anaphylactic reaction (SMQ)	Narrow	A	0	Active	11	Anaphylactic reaction (SMQ)
9	19	Bronchospasm	10006482	Bronchospasm	Anaphylactic reaction (SMQ)	Broad	B	0	Active	12	Anaphylactic reaction (SMQ)
10	20	Swelling face	10042682	Swelling face	Anaphylactic reaction (SMQ)	Broad	C	0	Active	12	Anaphylactic reaction (SMQ)
11	21	Rash	10037844	Rash	Anaphylactic reaction (SMQ)	Broad	C	0	Active	12	Anaphylactic reaction (SMQ)
12	22	Hypotension	10021097	Hypotension	Anaphylactic reaction (SMQ)	Broad	D	0	Active	12	Anaphylactic reaction (SMQ)
13	23	SLE arthritis	10040968	SLE arthritis	Systemic lupus erythematosus (SMQ)	Narrow	A	0	Active	13	Systemic lupus erythematosus (SMQ)
14	24	Haemolysis	10018910	Haemolysis	Systemic lupus erythematosus (SMQ)	Broad	H	3	Active	14	Systemic lupus erythematosus (SMQ)
15	25	Autoimmune nephritis	10077087	Autoimmune nephritis	Systemic lupus erythematosus (SMQ)	Broad	F	1	Active	14	Systemic lupus erythematosus (SMQ)
16	26	Double stranded DNA antibody positive	10069907	Double stranded DNA antibody positive	Systemic lupus erythematosus (SMQ)	Broad	I	3	Active	14	Systemic lupus erythematosus (SMQ)

000687


40




SMQ Applications

000687

41



SMQ Applications



```

graph LR
    A[Clinical Phase I] --> B[Clinical Phase II]
    B --> C[Clinical Phase III]
    C -.-> D[Marketed Product Phase IV]
  
```

- Clinical trials
 - Where safety profile is not fully established, use multiple SMQs on routine basis as screening tool
 - Selected SMQs to evaluate previously identified issue (pre-clinical data or class effect)

000687

42



MedDRA SMQ Applications (cont)




- Post-marketing
 - Selected SMQs to retrieve cases for suspected or known safety issue
 - Signal detection (multiple SMQs employed)
 - Single case alerts
 - Periodic reporting (aggregate cases for safety and other issues, e.g., lack of efficacy)

000687

43



MedDRA EMA: Signal Detection Analysis

- ICSR coding at LLT level, analysis at PT level (medical concept):
 - ✓ It may be important to conduct analysis at **higher level** of hierarchy: SOC, HLT, HLGT, HLT
 - When doing so, impact of axial and non multi-axial SOCs needs to be taken into account: relevant PTs in more than 1 SOC
 - ✓ It may be important to conduct analysis at **SMQ** level to maximise likelihood that all terms related to a specific medical condition of interest are identified
- Challenge: strike the correct **balance**

 - ✓ Too narrowly focused search (specificity): exclude events of potential relevance
 - ✓ Too broad search (sensitivity): difficult to identify a trend or signal that may require further analysis (incl. case review)

000687

Acknowledgement: Dr. Aniello Santoro, EMA

44



Use of SMQs at FDA – Reviewing Prescribing Information

- Proposed Prescribing Information:
- Warnings & Precautions:
 - Dizziness/Somnolence
 - Withdrawal of Antiepileptic Drugs
 - Suicidal Behavior and Ideation (class labeling)
- Final Prescribing Information
- **Boxed Warning:**
 - **Serious Psychiatric and Behavioral Reactions**
- Warnings & Precautions:
 - Falls
 - Dizziness & somnolence
 - Withdrawal of Antiepileptic Drugs
 - Suicidal Behavior and Ideation (class labeling)

SMQ (Narrow Search)	RR
(1) Hostility/aggression	4.4
(2) Vestibular disorders	4.258
(1) Hearing and vestibular disorders	4.088
(1) Hyponatraemia/SIADH	3.832
(2) Hearing impairment	3.832
(1) Dyslipidaemia *	2.555
(1) Biliary disorders	2.135
(2) Functional, inflammatory and gallstone related biliary disorders	2.135

000687

45



Two SMQ Data Analysis Scenarios

000687

46



MedDRA

Scenario #1

- Your company started development of a new drug for onychomycosis projected to take eight years and cost \$1.2 billion dollars

000687

47



MedDRA

Onychomycosis



Toe Nail Fungus

000687

48



MedDRA

Scenario #1 (cont)

- As part of safety surveillance, you decide to periodically run SMQs for serious AEs against your data
- You identify five possible cases of hemolytic anemia in your 1,000 patient exposures
- Based on this unfavorable risk/benefit ratio (remember, your drug is for nail fungus), you suggest stopping the development project

000687

49



MedDRA

Scenario #1 (cont)

- Your management reviews and follows your recommendation saving time, money and potential patient risk

Job well done !!!!!!!

000687

50



MedDRA

Scenario #2

- You are developing the fourth drug in a therapeutic class
- Other products in class are associated with development of high blood pressure and angioedema but, given the seriousness of the target disease, this is an acceptable risk

000687

51




MedDRA

Scenario #2 (cont)

- During development and early post-marketing on your product, you routinely run *Hypertension (SMQ)* and *Angioedema (SMQ)* against your expanding safety data
- Over time, it becomes clear that your drug is not associated with either of these risks for the other drugs in your therapeutic class
- Your diligence has given patients a safer alternative for the treatment of their disease

000687


52



Customized Searches

000687

53



Customized Searches – Modified SMQs

- Do not modify SMQ unless there is a compelling reason – makes it non-standard
- **“Modified MedDRA query based on an SMQ”**
 - ✓ To be used to refer to an SMQ that has been modified
 - ✓ All modifications must be documented
 - ✓ Version updates and maintenance are responsibility of organization that created it
 - ✓ SMQ *Lack of efficacy/effect* often modified based on particular product

000687

54



Customized Searches – *Ad Hoc* Queries

- Need medical knowledge
- Need knowledge of structure and characteristics of MedDRA and of your data
- Refer to the *MedDRA Data Retrieval and Presentation: Points to Consider* document for query construction tips
- Save query for future use; maintenance needed for MedDRA version changes
- Consider submitting *ad hoc* query to MSSO via change request for possible development as an SMQ

000687

55



Summary

- ✓ Reviewed the *MedDRA Data Retrieval and Presentation: Points to Consider* document
- ✓ Discussed the characteristics, uses, applications and benefits of Standardised MedDRA Queries (SMQs) including their customization

000687

56



MedDRA

MSSO Contacts

- Website
 - www.meddra.org
- Email
 - mssohelp@meddra.org
- Frequently Asked Questions
 - www.meddra.org/faq
- MedDRA Browsers
 - <https://www.meddra.org/meddra-desktop-browsers> (Desktop Browser)
 - <https://tools.meddra.org/wbb/> (Web-Based Browser)
 - <https://mmb.meddra.org> (Mobile Browser)

000687

57



MedDRA

MSSO Contacts (cont)

- Training Schedule
 - <https://www.meddra.org/training/schedule>
- MedDRA Support Documentation
 - <https://www.meddra.org/how-to-use/support-documentation>

000687

58



Question and Answer Session

000687

59